Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker JNJ · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 5, 2026 | RYBREVANT FASPRO AMIVANTAMAB AND HYALURONIDASE-LPUJ | JNJ Janssen Biotech | Biologic (BLA), supplement Efficacy | BLA761433 ↗ |
| Oct 30, 2026 | Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoel… AID, SURGICAL, VISCOELASTIC | JNJ Johnson & Johnson Surgical Vision, Inc. | Device approval (PMA), supplement Real-Time Process | P810031 ↗ |
| Oct 27, 2026 | TRACLEER BOSENTAN | JNJ Actelion | New drug (NDA), supplement REMS | NDA209279 ↗ |
| Oct 27, 2026 | TRACLEER BOSENTAN | JNJ Actelion | New drug (NDA), supplement REMS | NDA021290 ↗ |
| Sep 21, 2026 | Attune Revision Knee System Prosthesis, knee, patellofemorotibial, semi-constrained, me… | JNJ Depuy, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P830055 ↗ |
| Sep 17, 2026 | SPRAVATO ESKETAMINE HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA211243 ↗ |
| Sep 17, 2026 | HARMONIC 1100 Shears (HAR1120); HARMONIC 1100 Shears (HAR11… | JNJ Ethicon Endo-Surgery, LLC | Device clearance (510(k)) Traditional | K254196 ↗ |
| Sep 4, 2026 | ATTUNE Revision Knee System | JNJ Depuy Orthopaedics, Inc. | Device clearance (510(k)) Traditional | K262130 ↗ |
| Sep 2, 2026 | THERMOCOOL SMARTTOUCH® SF Catheter catheter, percutaneous, cardiac ablation, for treatment of… | JNJ Biosense Webster, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P030031 ↗ |
| Aug 28, 2026 | STELARA USTEKINUMAB | JNJ Janssen Biotech | Biologic (BLA), supplement Efficacy | BLA761044 ↗ |
| Aug 27, 2026 | ETHIZIA Hemostatic Patch Agent, absorbable hemostatic, collagen with polymeric addit… | JNJ Ethicon, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P240035 ↗ |
| Aug 24, 2026 | IMAAVY NIPOCALIMAB-AAHU | JNJ Janssen Biotech | Biologic (BLA), supplement Efficacy | BLA761430 ↗ |
| Aug 11, 2026 | INVOKAMET XR CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA205879 ↗ |
| Aug 11, 2026 | INVOKAMET XR CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA205879 ↗ |
| Aug 11, 2026 | INVOKAMET CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA204353 ↗ |
| Aug 11, 2026 | INVOKAMET CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA204353 ↗ |
| Aug 5, 2026 | ATTUNE Revision Knee System Prosthesis, knee, patellofemorotibial, semi-constrained, me… | JNJ Depuy, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P830055 ↗ |
| Jul 28, 2026 | SURGICELTM POWDER Absorbable Hemostatic Powder Agent, absorbable hemostatic, non-collagen based | JNJ Ethicon, Inc. | Device approval (PMA), supplement Normal 180 Day Track | N12159 ↗ |
| Jul 27, 2026 | Shockwave Intravascular Lithotripsy (IVL) System with the S… | JNJ Shockwave Medical, Inc. | Device clearance (510(k)) Special | K262201 ↗ |
| Jul 25, 2026 | MONARCH Platform (MON-000008) | JNJ Auris Health, Inc. | Device clearance (510(k)) Traditional | K260382 ↗ |
| Jul 21, 2026 | OTTAVA Robotic Surgical System | JNJ Auris Health, Inc., part of Johnson & Johnson MedTech | Device clearance (510(k)) De Novo | DEN250068 ↗ |
| Jul 15, 2026 | STELARA USTEKINUMAB | JNJ Janssen Biotech | Biologic (BLA), supplement Labeling | BLA761044 ↗ |
| Jul 7, 2026 | SPORANOX ITRACONAZOLE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA020657 ↗ |
| Jul 7, 2026 | SPORANOX, ITRACONAZOLE ITRACONAZOLE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA020083 ↗ |
| Jul 1, 2026 | Dual Energy THERMOCOOL SMARTTOUCH SF System catheter, percutaneous, cardiac ablation, for treatment of… | JNJ Biosense Webster, Inc. | Device approval (PMA), supplement Panel Track | P030031 ↗ |
| Jun 30, 2026 | VARIPULSE Catheter, TRUPULSE Generator with Connection In… Percutaneous Cardiac Ablation Catheter for Treatment of Atr… | JNJ Biosense Webster, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P240006 ↗ |
| Jun 30, 2026 | VISITAG SURPOINT External Processing Unit (EPU); CARTO 3… catheter, percutaneous, cardiac ablation, for treatment of… | JNJ Biosense Webster, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P030031 ↗ |
| Jun 29, 2026 | LCS® Total Knee System Prosthesis, knee, patellofemorotibial, semi-constrained, me… | JNJ Depuy, Inc. | Device approval (PMA), supplement Special (Immediate Track) | P830055 ↗ |
| Jun 29, 2026 | ERLEADA APALUTAMIDE | JNJ Janssen Biotech | New drug (NDA), supplement Labeling | NDA210951 ↗ |
| Jun 25, 2026 | ETHIZIA Hemostatic Patch Agent, absorbable hemostatic, collagen with polymeric addit… | JNJ Ethicon, Inc. | Device approval (PMA), supplement Panel Track | P240035 ↗ |
| Jun 25, 2026 | ATTUNE Total Knee System; ATTUNE Cementless Knee System | JNJ DePuy Ireland UC | Device clearance (510(k)) Traditional | K261458 ↗ |
| Jun 25, 2026 | VELYS Robotic-Assisted Solution | JNJ Depuy Ireland UC | Device clearance (510(k)) Traditional | K260480 ↗ |
| Jun 25, 2026 | Coated VICRYL (Polyglactin 910) Plus Antibacterial Suture | JNJ Ethicon, Inc. | Device clearance (510(k)) Traditional | K253394 ↗ |
| Jun 24, 2026 | Shockwave lntravascular Lithotripsy (IVL) System with Shoc… Shockwave intravascular lithotripsy system | JNJ Shockwave Medical, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P200039 ↗ |
| Jun 24, 2026 | SPRAVATO ESKETAMINE HYDROCHLORIDE | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement REMS | NDA211243 ↗ |
| Jun 15, 2026 | Impella CP with SmartAssist Temporary non-roller type left heart support blood pump | JNJ Abiomed, Inc. | Device approval (PMA), supplement Special (Immediate Track) | P140003 ↗ |
| Jun 3, 2026 | INVOKANA CANAGLIFLOZIN | JNJ Janssen Pharmaceuticals | New drug (NDA), supplement Labeling | NDA204042 ↗ |
| May 28, 2026 | TREMFYA GUSELKUMAB | JNJ Janssen Biotech | Biologic (BLA), supplement Efficacy | BLA761061 ↗ |
| May 28, 2026 | DARZALEX DARATUMUMAB | JNJ Janssen Biotech | Biologic (BLA), supplement Labeling | BLA761036 ↗ |
| May 23, 2026 | UPTRAVI SELEXIPAG | JNJ Actelion | New drug (NDA), supplement Labeling | NDA214275 ↗ Letter or label ↗ |
| May 23, 2026 | UPTRAVI, UPTRAVI TITRATION PACK SELEXIPAG | JNJ Actelion | New drug (NDA), supplement Labeling | NDA207947 ↗ Letter or label ↗ |
| May 23, 2026 | UPTRAVI, UPTRAVI TITRATION PACK SELEXIPAG | JNJ Actelion | New drug (NDA), supplement Efficacy | NDA207947 ↗ Letter or label ↗ |
| May 22, 2026 | DePuy ATTUNE Knee System | JNJ DePuy Orthopaedics, Inc. | Device clearance (510(k)) Traditional | K252887 ↗ |
| May 19, 2026 | TECNIS Eyhance Toric II IOLs with SmartLOAD Delivery Tech… LENS, INTRAOCULAR, TORIC OPTICS | JNJ Johnson & Johnson Surgical Vision, Inc. | Device approval (PMA), supplement Real-Time Process | P980040 ↗ |
| May 18, 2026 | STRATAFIX Symmetric PDS Plus Knotless Tissue Control Devi… | JNJ Ethicon, Inc. | Device clearance (510(k)) Traditional | K252047 ↗ |
| May 15, 2026 | Prostalac Hip System, SmartSet V+G Dual Antibiotic Bone Cem… | JNJ Depuy Ireland UC | Device clearance (510(k)) Traditional | K260536 ↗ |
| May 11, 2026 | ETHICON Circular Stapler (CDH21mm); ETHICON Circular Stap… | JNJ Ethicon Endo-Surgery, LLC | Device clearance (510(k)) Traditional | K260196 ↗ |
| May 6, 2026 | TALVEY TALQUETAMAB-TGVS | JNJ Janssen Biotech | Biologic (BLA), supplement REMS | BLA761342 ↗ Letter or label ↗ |
| May 6, 2026 | TECVAYLI TECLISTAMAB-CQYV | JNJ Janssen Biotech | Biologic (BLA), supplement REMS | BLA761291 ↗ Letter or label ↗ |
| Apr 30, 2026 | LAZCLUZE LAZERTINIB MESYLATE | JNJ Janssen Biotech | New drug (NDA), supplement Labeling | NDA219008 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates